A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients

NCT03006159 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetic Patients

Interventions

DRUG: SHR0534
DRUG: Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.